Onkologie. 2014:8(1):35-38

Thoracoscopic chemically induced pleurodesis in the treatment of malignant pleural effusion

Petr Habal1, Nedal Omran1, Karolina Jankovičová2, Kateřina Kondělková2, Jan Krejsek2, Jiří Manďák1
1 Kardiochirurgická klinika, Univerzita Karlova v Praze, LF a FN v Hradci Králové
2 Ústav klinické imunologie a alergologie, Univerzita Karlova v Praze, LF a FN v Hradci Králové

Continuous pleural effusion production of any aetiology can significantly affect the quality of patients life. Chronic effusion accumulation

in the pleural cavity can lead to lung parenchyma compression. The first symptom of this entity is a progressive exertional dyspnea, which

can later turn in dyspnea at rest. With the increase of the pleural effusion volume, pulmonary atelectasis can develop due to chronic parenchycha

compression. The patient is at risk of inflamatory complications from the territory of non-ventilated parenchyma. Patients with

a diagnosis of malignant disease have this risk considerably higher due to their previous chemotherapy or radiation, which substantially

affect the immunity system. Repeated pleural effusion formation can significantly take part in the development of the terminal status of

cancer cachexia. An effective method of palliative treatment is a chemical pleurodesis, which is used in selected patients. The principle

is inducing aseptic inflammation. The most effective way of application is via videothoracoscopy. In a group of 47 patients, there were

29 (61.7 %) men and 18 (38.3 %) women with cytologically diagnosed recurrent malignant pleural. The age ranged between 42 and 80

with average age of 65 years. The aim was to assess the course of local and systemic inflammatory changes after talc application. The

effect of treatment was not influenced by the type of malignancy . In both groups there was no significant difference in postoperative

complications. This proves the safety of the selected procedure and also supports the correctness of the chosen algorithm of treatment.

Keywords: malign pleural effusion, thoracoscopy, talc poudrage, sCD-163

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Habal P, Omran N, Jankovičová K, Kondělková K, Krejsek J, Manďák J. Thoracoscopic chemically induced pleurodesis in the treatment of malignant pleural effusion. Onkologie. 2014;8(1):35-38.
Download citation

References

  1. Miserocchi G. Physiology of pleural fluid turnover. Eur Respir J 1997; 10: 219-225. Go to original source... Go to PubMed...
  2. Agostini E. Mechanics of the pleural space. Handbook of physiology: the respiratory system. Mechanics of breathing. Baltimore: American Physiologcal Society 1986; 24: 531-539. Go to original source...
  3. Agostini E, Zocchi L. Mechanical coupling and liquid exchanges in the pleural space. Clin Chest Med 1998; 19: 241-260. Go to original source... Go to PubMed...
  4. Jantz MA, Antony VB. Pathophysiology of the pleura. Respiration 2008; 75: 121-133. Go to original source... Go to PubMed...
  5. Marel M, Zrustova M, Stastny B. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest 1993; 104: 1486-1489. Go to original source... Go to PubMed...
  6. Burrows CM, Mathews WC Colt, HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117: 73-78. Go to original source... Go to PubMed...
  7. Schag CC, Heinrich Ganz PA. Karnofsky performance status revisited. Reliability, validity, and guidelines. J Clin Oncology 1984; 2: 187-193. Go to original source... Go to PubMed...
  8. Huggins JT, Doelken P, Sahn SA. The unexpadable lung. Med Rep 2010; 2: 77. Go to original source...
  9. 9. Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F, Loddenkemper R, Herth FJ, Gasparini S, Marquette CH, Becke B, Froudarakis ME, Driesen P, Bolliger CT, Tschopp JM. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369: 1535-1539.
  10. Rodriguez-Panadero F, Montes-Worboys A. Mechanisms of pleurodesis. Respiration 2012; 83: 91-98. Go to original source... Go to PubMed...
  11. Montes JF, Ferrer J, Villarino MA. Influence of talc dose on extrapleural talc dissemination after talc pleurodesis. Am J Respir Crit Care Med 2003; 168: 348-355. Go to original source... Go to PubMed...
  12. Bethune N. Pleural poudrage: new technique for deliberate production of pleural adhesion as preliminary to lobectomy. J Thorac Surg 1935; 4: 251-261. Go to original source...
  13. Davies R, Skidmore JW, Griffiths DM, Moncrieff CB. Cytotoxicity of talc for macrophages in vitro. Food Chem Toxicol 1983; 21: 201-207. Go to original source... Go to PubMed...
  14. Porcel JM. Pearls and myths in pleural fluid analysis. Respirology 2011; 16: 44-52. Go to original source... Go to PubMed...
  15. Delongu G, Moretti S, Antonucci A. Apoptosis and surgical trauma. Arch Surg 2000; 135:1141-1147. Go to original source... Go to PubMed...
  16. Levy JH, Tanak KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: 715-720. Go to original source... Go to PubMed...
  17. Yang HB, Xie KQ, Deng JM, Qin SM. Expression of soluble Toll-like receptors in pleural effusions. Chin Med J 2010; 123: 2225-2230.
  18. Krejsek J, Kunes P, Kolackova M, Kudlova M, Lonsky V, Mandak J, Andrys C. Expression of Toll-like receptors 2 and 4 on innate immunity cells modulated by cardiac surgical operation. Scand J Clin Lab Invest 2008; 68: 749-758. Go to original source... Go to PubMed...
  19. Onofre G, Kolackova M, Jankovicova K. Scavenger receptor cd163 and its biological functions. Acta medica (Hradec Kralove) 2009; 52 (2): 57-61. Go to original source...
  20. Hidaka M, Fukuzawa K. Down-modulation of toll-like receptor 2 expression on granulocytes and suppression of interleukin-8 production due to in vitro treatment with cellulose acetate beads. Ther Apher Dial 2011; 15: 572-578. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.